Impact of an Integrated Model of Care on Outcomes of Patients With Inflammatory Bowel Diseases: Evidence From a Population-Based Study

J Crohns Colitis. 2017 Dec 4;11(12):1471-1479. doi: 10.1093/ecco-jcc/jjx106.

Abstract

Background and aims: Studies evaluating the impact of integrated models of care [IMC] for inflammatory bowel disease [IBD] on disease-related outcomes are needed. We compared the risk of IBD-related outcomes and prescription medication claims between patients exposed and non-exposed to an IMC.

Methods: A retrospective population-based matched cohort study was conducted between 2009 and 2015, using administrative health data of Saskatchewan, Canada. Patients aged 18+ years with a diagnosis of IBD were identified with a validated administrative definition. Cases were classified as exposed and non-exposed to the IMC for IBD and matched based on propensity scores and disease duration. IBD-related hospitalisations, surgeries, prescription medication claims, and corticosteroid dependency [CsDep] were measured. Cox and logistic regression models evaluated differences between the groups, estimating hazard [HRs] and odds [ORs] ratios with corresponding confidence intervals [CIs].

Results: In total, 2312 matched patients were included; 24.3% were exposed individuals. Compared with non-exposed, exposed patients had a lower risk of IBD-related surgeries [HR = 0.78, 95% CI 0.61-0.99], higher risk of prescriptions of immune modulators [HR = 1.68, 95% CI 1.42-1.99], and biologics [HR = 1.85, 95% CI 1.52-2.27], and a lower risk of 5-aminosalicylic acid prescriptions [HR = 0.81, 95% CI 0.69-0.95]. A lower risk of IBD-related hospitalisations among exposed ulcerative colitis [UC] patients [HR = 0.66, 95% CI 0.49-0.89] was identified in stratified analyses. The odds of CsDep among exposed UC patients was 0.39 [95% CI 0.15-0.98].

Conclusions: The observed differences in disease-related outcomes and use of steroid-sparing maintenance therapies between exposed and non-exposed individuals support the concept that enhanced quality of care can be achieved within IMC for IBD.

Keywords: Crohn’s disease; Integrated delivery of health care; health administrative data; quality of health care; ulcerative colitis.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biological Factors / therapeutic use
  • Delivery of Health Care / organization & administration*
  • Delivery of Health Care / standards
  • Delivery of Health Care / statistics & numerical data*
  • Digestive System Surgical Procedures / statistics & numerical data*
  • Drug Prescriptions / statistics & numerical data*
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Immunologic Factors / therapeutic use
  • Inflammatory Bowel Diseases / therapy*
  • Male
  • Mesalamine / therapeutic use
  • Middle Aged
  • Quality of Health Care*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Biological Factors
  • Immunologic Factors
  • Mesalamine